X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13847) 13847
Newsletter (1122) 1122
Dissertation (46) 46
Book Chapter (43) 43
Newspaper Article (42) 42
Magazine Article (40) 40
Report (6) 6
Book Review (4) 4
Conference Proceeding (4) 4
Publication (3) 3
Web Resource (3) 3
Reference (1) 1
Streaming Video (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10004) 10004
lamivudine (9359) 9359
male (5487) 5487
female (5283) 5283
adult (4905) 4905
lamivudine - therapeutic use (4266) 4266
hepatitis b (3888) 3888
middle aged (3750) 3750
antiviral agents - therapeutic use (3370) 3370
hepatitis b, chronic - drug therapy (3096) 3096
hiv infections - drug therapy (3011) 3011
infectious diseases (3000) 3000
gastroenterology & hepatology (2854) 2854
hepatitis b virus (2474) 2474
treatment outcome (2442) 2442
therapy (2273) 2273
drug therapy, combination (2213) 2213
virology (2173) 2173
hepatitis b virus - genetics (2070) 2070
hiv (1955) 1955
anti-hiv agents - therapeutic use (1936) 1936
infection (1883) 1883
pharmacology & pharmacy (1795) 1795
viral load (1757) 1757
tenofovir (1688) 1688
reverse transcriptase inhibitors - therapeutic use (1687) 1687
immunology (1685) 1685
hepatitis b virus - drug effects (1631) 1631
adenine - analogs & derivatives (1549) 1549
lamivudine - administration & dosage (1514) 1514
antiviral agents (1509) 1509
mutation (1489) 1489
drug therapy (1479) 1479
zidovudine (1411) 1411
aged (1392) 1392
health aspects (1318) 1318
care and treatment (1303) 1303
dna, viral - blood (1293) 1293
entecavir (1266) 1266
adefovir dipivoxil (1258) 1258
hepatitis b, chronic - virology (1253) 1253
research (1236) 1236
hepatitis (1171) 1171
antiretroviral therapy (1155) 1155
hepatitis b - drug therapy (1155) 1155
adenine - therapeutic use (1123) 1123
adolescent (1118) 1118
chronic hepatitis b (1100) 1100
hiv infections - virology (1069) 1069
microbiology (1037) 1037
resistance (1037) 1037
drug resistance, viral (1035) 1035
lamivudine - pharmacology (1034) 1034
interferon (1024) 1024
retrospective studies (1010) 1010
zidovudine - therapeutic use (1006) 1006
organophosphonates - therapeutic use (992) 992
drug resistance (934) 934
virus diseases (933) 933
hiv-1 - drug effects (932) 932
analysis (931) 931
efficacy (924) 924
hepatitis b e antigens - blood (919) 919
genotype (904) 904
cd4 lymphocyte count (901) 901
time factors (880) 880
risk factors (875) 875
guanine - analogs & derivatives (873) 873
dna (871) 871
antiviral agents - administration & dosage (848) 848
young adult (848) 848
anti-hiv agents - administration & dosage (845) 845
combination (838) 838
antiviral agents - pharmacology (831) 831
hiv infection (818) 818
transplantation (791) 791
replication (774) 774
lamivudine - adverse effects (773) 773
adefovir (764) 764
aids (758) 758
mutations (747) 747
human immunodeficiency virus--hiv (745) 745
liver (743) 743
liver transplantation (722) 722
medicine, general & internal (721) 721
prevention (711) 711
hbv (699) 699
hepatocellular-carcinoma (697) 697
follow-up studies (690) 690
recurrence (686) 686
virus (685) 685
hepatitis b surface antigens - blood (668) 668
anti-hiv agents - adverse effects (667) 667
hepatitis b virus - immunology (667) 667
hiv-1 (664) 664
drug resistance, viral - genetics (661) 661
hiv-1 - genetics (657) 657
guanine - therapeutic use (648) 648
antiretroviral drugs (647) 647
medical research (642) 642
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13998) 13998
Korean (322) 322
Chinese (295) 295
French (184) 184
Spanish (156) 156
German (145) 145
Portuguese (116) 116
Japanese (111) 111
Polish (40) 40
Hungarian (27) 27
Russian (27) 27
Turkish (27) 27
Czech (14) 14
Dutch (13) 13
Italian (12) 12
Danish (6) 6
Romanian (3) 3
Serbian (3) 3
Croatian (2) 2
Lithuanian (2) 2
Swedish (2) 2
Arabic (1) 1
Finnish (1) 1
Hebrew (1) 1
Norwegian (1) 1
Persian (1) 1
Slovak (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drugs, ISSN 0012-6667, 07/1999, Volume 58, Issue 1, pp. 101 - 141
Lamivudine is a deoxycytidine analogue that is active against hepatitis B virus (HBV). In patients with chronic hepatitis B, lamivudine profoundly suppresses... 
Reviews-on-treatment | Antivirals, therapeutic-use | Clinical-pharmacokinetics | Lamivudine, pharmacokinetics | Lamivudine, general | Interferon-alpha, therapeutic-use | Hepatitis-B, treatment | Liver-transplant | Immune-function | HIV-infections | Famciclovir, therapeutic-use | Lamivudine, therapeutic-use | Lamivudine, pharmacodynamics | Lamivudine, adverse-reactions | Drug-evaluations | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Lamivudine | Pharmacodynamics | Pharmacokinetics | Therapeutic use | Hepatitis B | FIBROSING CHOLESTATIC HEPATITIS | NUCLEOSIDE ANALOGS | hepatitis B | pharmacodynamics | ORTHOTOPIC LIVER-TRANSPLANTATION | REVERSE-TRANSCRIPTASE | HUMAN-IMMUNODEFICIENCY-VIRUS | HEPATOCELLULAR-CARCINOMA | HIV-INFECTION | pharmacokinetics | PHARMACOLOGY & PHARMACY | SURFACE-ANTIGEN | TOXICOLOGY | therapeutic use | CHRONIC VIRAL-HEPATITIS | INTERFERON-ALPHA THERAPY | lamivudine | Lamivudine - administration & dosage | Humans | Reverse Transcriptase Inhibitors - pharmacology | Lamivudine - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hepatitis B, Chronic - virology | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - pharmacokinetics | Animals | Hepatitis B, Chronic - drug therapy | Lamivudine - therapeutic use | Lamivudine - pharmacology | Reverse Transcriptase Inhibitors - therapeutic use
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2009, Volume 136, Issue 2, pp. 486 - 495
Background & Aims The GLOBE trial has compared the efficacy and safety of telbivudine versus lamivudine treatment over 2 years in patients with chronic... 
Gastroenterology and Hepatology | E-ANTIGEN | ENTECAVIR | THERAPY | VIRUS | POSITIVE CHRONIC HEPATITIS | ADEFOVIR DIPIVOXIL | RESISTANCE | RISK | NATURAL-HISTORY | YMDD VARIANTS | GASTROENTEROLOGY & HEPATOLOGY | Prospective Studies | Humans | Middle Aged | Male | Alanine Transaminase - blood | Hepatitis B Surface Antigens - blood | Lamivudine - adverse effects | Young Adult | Lamivudine - therapeutic use | Nucleosides - pharmacology | Adult | Female | Hepatitis B, Chronic - blood | Pyrimidinones - pharmacology | Hepatitis B virus - immunology | Nucleosides - therapeutic use | Virus Replication - drug effects | Antiviral Agents - pharmacology | DNA, Viral - drug effects | Double-Blind Method | Global Health | Antiviral Agents - therapeutic use | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Treatment Outcome | Nucleosides - adverse effects | Regression Analysis | Hepatitis B, Chronic - drug therapy | Thymidine - analogs & derivatives | Antiviral Agents - adverse effects | Adolescent | Hepatitis B virus - genetics | Aged | Lamivudine - pharmacology | Hepatitis B e Antigens - blood | Longitudinal Studies | Polymerase chain reaction | Care and treatment | Creatine kinase | Analysis | Gastrointestinal diseases | Clinical trials | Lamivudine | Creatine | Hepatitis B | Index Medicus | Abridged Index Medicus
Journal Article
The Journal of infectious diseases, ISSN 0022-1899, 10/2008, Volume 198, Issue 8, pp. 1113 - 1122
Background. Vicriviroc (VCV) is a CCR5 antagonist with nanomolar activity against human immunodeficiency virus (HIV) replication in vitro and in vivo. We... 
HIV/AIDS | Tropisms | RNA | HIV | Placebos | Viruses | AIDS | Infections | Dosage | HIV 1 | Virology | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | MICROBIOLOGY | IMMUNOLOGY | HUMAN-IMMUNODEFICIENCY-VIRUS | PROGNOSTIC VALUE | CCR5 ANTAGONIST | INDIVIDUALS | ANTIRETROVIRAL-DRUG-RESISTANCE | SYNCYTIUM-INDUCING PHENOTYPE | EPIDEMIOLOGY | DISEASE PROGRESSION | Piperazines - administration & dosage | Lamivudine - administration & dosage | Humans | Male | RNA, Viral - blood | Reverse Transcriptase Inhibitors - administration & dosage | Viral Load | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | HIV-1 - physiology | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | CCR5 Receptor Antagonists | Benzoxazines - administration & dosage | Double-Blind Method | Zidovudine - adverse effects | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | HIV Infections - virology | Benzoxazines - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Piperazines - therapeutic use | Piperazines - adverse effects | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | HIV Infections - drug therapy | Zidovudine - therapeutic use | Lamivudine | Dosage and administration | HIV (Viruses) | Drug therapy | Zidovudine | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 19, pp. 1807 - 1818
Journal Article
by Gregson, John and Tang, Michele and Ndembi, Nicaise and Hamers, Raph L and Rhee, Soo-Yon and Marconi, Vincent C and Diero, Lameck and Brooks, Katherine A and Theys, Kristof and Rinke de Wit, Tobias and Arruda, Monica and Garcia, Frederico and Monge, Susana and Günthard, Huldrych F and Hoffmann, Christopher J and Kanki, Phyllis J and Kumarasamy, Nagalingeshwaran and Kerschberger, Bernard and Mor, Orna and Charpentier, Charlotte and Todesco, Eva and Rokx, Casper and Gras, Luuk and Helvas, Elias K and Sunpath, Henry and Di Carlo, Domenico and Antinori, Antonio and Andreoni, Massimo and Latini, Alessandra and Mussini, Cristina and Aghokeng, Avelin and Sonnerborg, Anders and Neogi, Ujjwal and Fessel, William J and Agolory, Simon and Yang, Chunfu and Blanco, Jose L and Juma, James M and Smit, Erasmus and Schmidt, Daniel and Watera, Christine and Asio, Juliet and Kurungi, Wilford and Tostevin, Anna and El-Hay, Tal and Clumeck, Nathan and Goedhals, Dominique and Van Vuuren, Cloete and Bester, Philip A and Sabin, Caroline and Mukui, Irene and Santoro, MARIA M and Perno, Carlo F and Hunt, Gillian and Morris, Lynn and Camacho, Ricardo and De Oliveira, Tulio and Pillay, Deenan and Schulter, Eugene and Murakami-Ogasawara, Akio and Reyes-Terán, Gustavo and Romero, Karla and Avila-Rios, Santiago and Sirivichayakul, Sunee and Ruxrungtham, Kiat and Mekprasan, Suwanna and Dunn, David and Kaleebu, Pontiano and Raizes, Elliot and Kantor, Rami and Shafer, Robert W and Gupta, Ravindra K and The TenoRes Study Group and TenoRes Study Grp
The Lancet infectious diseases, ISSN 1473-3099, 2016, Volume 16, Issue 5, pp. 565 - 575
Journal Article
PloS one, ISSN 1932-6203, 11/2013, Volume 8, Issue 11, p. e79981
Introduction: Lamivudine and emtricitabine are considered equivalent by several guidelines, but evidence of comparable efficacy is conflicting. Methods: We... 
PROTEASE INHIBITOR | TENOFOVIR-EMTRICITABINE | ANTIRETROVIRAL-NAIVE | SUPPRESSED PATIENTS | MULTIDISCIPLINARY SCIENCES | DOUBLE-BLIND | ABACAVIR/LAMIVUDINE | FIXED-DOSE ZIDOVUDINE/LAMIVUDINE | RETROVIRAL-NAIVE PATIENTS | HIV-1-INFECTED PATIENTS | HIV-INFECTED PATIENTS | Emtricitabine | HIV-1 - drug effects | HIV Infections - virology | Humans | Male | Treatment Outcome | Lamivudine - pharmacokinetics | Randomized Controlled Trials as Topic | Deoxycytidine - pharmacokinetics | Deoxycytidine - therapeutic use | Reverse Transcriptase Inhibitors - pharmacokinetics | HIV-1 - growth & development | Anti-HIV Agents - pharmacokinetics | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Databases, Bibliographic | Reverse Transcriptase Inhibitors - therapeutic use | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Therapeutic Equivalency | Highly active antiretroviral therapy | Lamivudine | Analysis | Antiretroviral drugs | Identification methods | Clinical trials | Population studies | Risk | Systematic review | Patients | Antiretroviral therapy | Studies | Tenofovir | Randomization | Equivalence | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Abacavir | AIDS | HIV | Acquired immune deficiency syndrome | Human immunodeficiency virus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2007, Volume 357, Issue 25, pp. 2576 - 2588
Journal Article
12.